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Abstract
Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV
establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects
one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are
not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely,
in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases,
a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the
immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection
against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the
scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of
rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to
experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in
unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and
decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of
the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4
depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed
and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with
agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of
progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a
more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one
potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.
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Introduction
Varicella zoster virus (VZV), a neurotropic alphaherpesvirus, is
the causative agent of varicella (chickenpox). Following resolution
of the acute infection, VZV establishes latency in sensory ganglia,
and can reactivate years later, manifesting as dermatomal vesicular
lesions known as herpes zoster (HZ, shingles) [1]. HZ is a painful
and debilitating disease that causes significant morbidity such as
post-herpetic neuralgia and HZ opthalmicus [2,3] and occasion-
ally mortality in the elderly and immune compromised [4]. HZ
affects 1 million people each year in the United States [5,6] and
persons older than 60 year of age account for 40–50% of HZ cases
reported each year [5,6]. Given that by 2020 17% of the US
population is estimated to be 65 years of age or older (US Census),
the incidence of HZ and its associated morbidities is likely to
increase.
There are currently two FDA approved VZV vaccines available
that contain the live attenuated VZV Oka strain: Varivax, directed
against chickenpox, and Zostavax, directed against shingles. The
introduction of Varivax, and more specifically of the 2-dose
regimen, has dramatically reduced the incidence of chickenpox
and annual varicella-related hospitalizations and deaths in the US
[7,8]. Similarly, vaccination with Zostavax reduced the incidence
of shingles by 51% in a 3-year study period and resulted in a 61%
decrease in the burden of disease [9,10]. However, it is important
to note that the efficacy of Zostavax was reduced in individuals
older than 70 years [9]. Moreover, recent studies showed that the
cellular and humoral responses engendered by Zostavax signifi-
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that the proportion of persons 85 years and older is expected to
increase from 14% in 2010 to more than 21% in 2050 (US Census
Bureau, 2010), new vaccination strategies against VZV should be
explored.
Clinical observations suggest that the successful resolution of
acute VZV infection is associated with the development of the
host’s VZV-specific cellular immunity rather than humoral
immunity [1,12,13,14,15,16]. Specifically, children suffering from
congenital immune deficiencies affecting cellular immunity or
from hematological malignancies, or undergoing immunosuppres-
sive treatment are at risk for progressive varicella; whereas,
children with agammaglobulinemia have uncomplicated varicella
episodes [17,18,19,20,21]. Transfusion of lymphocytes from
immune donors to children with immunodeficiencies can limit
VZV infection and replication after the appearance of cutaneous
lesions [22]. In contrast, the administration of immunoglobulins
with high titers of IgG antibodies to VZV is only protective when
administered within 72 hours of exposure [23,24,25]. While early
production of VZV antibodies by HIV-infected children does not
prevent progressive varicella [26], absence of cellular immunity in
these children correlates with a risk of prolonged viremic phase,
continued formation of skin lesions and dissemination of the virus
to the lungs and other organs [16,27]. However, these data are
confounded by the fact that T cell-deficient patients lack both T
cell-mediated and T cell-dependent B cell-mediated responses.
Thus, more careful analyses of the contribution of each of the
major lymphocyte subsets are required.
Both VZV-specific CD4 and CD8 T cells are detected during
acute VZV infection [12,28]. CD4 Th1 cells, which produce the
anti-viral cytokine IFNc and have cytotoxic potential, predomi-
nate the VZV-specific T cell response [12,28], with little or no
production of Th2 cytokines [12]. Several studies have shown that
VZV-specific CD4 T cells recognize ORF4 [29], glycoprotein I
[30], and ORF63 [31]. In contrast to CD4 T cells, the specificity
and magnitude of VZV-specific CD8 T cell response are only
partially understood. Several studies have suggested that VZV-
specific CD8 T cells circulate at very low frequencies, possibly due
to immune evasion strategies such as MHC class I downregulation
[30,32,33]. However, it is also likely that the CD8 T cell response
is under-appreciated because VZV lysate used in the majority of
the studies is poorly presented via the MHC-I pathway [34].
Consequently, the role of CD8 versus CD4 T cell immunity in the
control of VZV infection remains unclear.
Our understanding of the importance of the T and B cell
responses to the resolution of VZV infection remains incomplete
because of the lack of adequate animal models. VZV infection of
small rodent models (guinea pigs, cotton rats, and mice) does not
result in varicella [35,36,37,38,39]. Dr. Arvin and colleagues
developed a SCID-humanized (SCID-hu) mouse model which has
significantly advanced our understanding of VZV pathogenesis
[40]. However, the immuno-deficient nature of the animals has
precluded the characterization of immune response to VZV
infection. Simian varicella virus (SVV) is a neurotropic alphaher-
pesvirus that naturally infects non-human primates (NHP) and
shares 75% DNA homology and genome colinearity with VZV
[41,42,43]. The exact mode of SVV transmission has not yet been
experimentally determined but it is believed to occur through
contact with skin lesions of an infected animal, or via exposure to
virus-laden aerosolized droplets from infected animal(s), as
described for VZV transmission in humans [44,45]. We have
recently shown that intrabronchial infection of rhesus macaques
(RM) with SVV recapitulates the hallmarks of acute VZV
infection in humans: (1) generalized varicella rash; (2) development
of cellular and humoral responses; (3) resolution of acute infection;
and (4) establishment of latency in sensory ganglia [46]. In our
model, the introduction of SVV directly into the lungs potentially
bypasses the initial stage of VZV replication that occurs in the
oropharynx, head and neck regions [47], which could affect viral
amplification within tonsilar memory T cell [40,48,49]. Despite
this potential difference, T and B cell responses develop with
similar kinetics relative to the onset of the exanthem in SVV
inoculated animals and children infected with VZV, thereby
providing a robust animal model with which to study anti-VZV
immunity.
The goal of this study was to identify the host immune responses
essential for protection against primary SVV infection in
unvaccinated RM as a model of VZV infection in humans. To
this end, we compared disease severity and immune response in
four groups of young RM infected with SVV: (1) control animals;
(2) CD20+ B cell depleted; (3) CD8+ T cell depleted; and (4) CD4+
T cell depleted. We show that loss of B cells during primary SVV
infection does not alter viral loads or disease severity. In contrast,
loss of CD8 T cells led to a slightly higher peak viral load and the
loss of CD4 T cells led to significantly higher viral loads and
disseminated varicella. These studies suggest that cellular immu-
nity and more specifically CD4 T cell immunity plays a critical
role in the control of SVV infection. These observations have
important ramifications for the development of novel vaccination
strategies to alleviate VZV associated diseases.
Results
Efficacy of depleting antibodies
The contributions of cellular versus humoral immune responses
in the resolution of acute VZV infection have not yet been
experimentally addressed. Therefore, using the infection of young
RM with SVV as a model of acute VZV infection, we aimed to
determine the role of T cell versus B cell responses during acute
SVV infection. Prior to intrabronchial SVV inoculation, 16 young
RM were divided into four groups of four animals each: (1)
control; (2) CD8+ T cell depleted; (3) CD4+ T cell depleted; and
(4) CD20+ B cell depleted. T and B cell depletion regimens were
Author Summary
Varicella zoster virus (VZV) causes chickenpox and
establishes a life-long latent infection in humans. VZV
can reactivate years later to cause shingles, a debilitating
and painful disease. Vaccines against both chickenpox and
shingles are available but not 100% efficacious. Two doses
of the chickenpox vaccine are required to provide
adequate protection and the shingles vaccine reduces
the incidence of this disease by 51%. To improve these
vaccines, we must identify the components of the immune
system that are important for the control of VZV
replication. However, the contribution of T versus B cell
responses is unknown. Infection of rhesus macaques with
simian varicella virus is a robust model of VZV infection.
Here, we used this unique animal model to show for the
first time that the absence of B cells does not alter disease
severity and that the loss of CD8 T cells only results in a
mild increase in disease severity. In sharp contrast, the lack
of CD4 T cells leads to disseminated varicella. These data
highlight the importance of CD4 T cells and suggest that
novel vaccines that focus on engendering a more robust
CD4 T cell response against VZV might provide better
protection from chickenpox and shingles.
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lymphocyte population was not present on the day of infection (0
dpi). The frequency of CD4+ T cells, CD8+ T cells, and CD20+ B
cells in peripheral blood mononuclear cells (PBMC) and bronchial
alveolar lavage (BAL) samples were monitored throughout the
study by flow cytometry (FCM). In contrast to peripheral blood,
frequency of CD20 B cells is very low in BAL (Fig. 1). Treatment
with CD20 depleting antibody resulted in the loss of B cells
beginning at 0 dpi and lasting until 21 dpi in BAL (Fig. 1C) and 17
dpi in peripheral blood (Fig. 1F). Administration of CD8-depleting
antibody resulted in complete loss of CD8+ T cells between 0 and
14 dpi in BAL (Fig. 1B) and between 0 and 17 dpi in peripheral
blood (Fig. 1E) Administration of anti-CD4 depleting antibody
decreased the frequency of CD4+ T cells on day 0 but complete
loss was not achieved until 10 dpi (Fig 1A and D). This loss was
very transient in BAL samples where the recovery started 14 dpi
(Fig. 1A). In peripheral blood, CD4 depletion lasted until 17 dpi
(Fig. 1D). In summary, CD20 and CD8 T cell depletions were
more profound (achieving ,100% loss by day 0) and lasted longer
than CD4 T cell depletion. Following depletion, recovery was very
slow in all three lymphocyte subsets and the frequencies did not
return to baseline by the end of the study.
Impact of T and B cell loss on SVV viral loads and disease
severity
To determine the impact of T and B cell loss on SVV
replication, we measured viral loads in whole blood (WB), BAL
and buccal swabs by qPCR. As previously reported [46], SVV
viral loads in WB were detected in non-depleted control animals 3
dpi, peaked at 7 dpi, and resolved at 21 dpi in WB (Fig. 2A) and
BAL (Fig. 2B). CD20 depleted animals showed comparable viral
loads and viral replication kinetics as those observed in non-
depleted animals (Fig. 2A and 2B). In contrast, CD4+ depleted
animals showed the highest peak SVV viral loads in WB at 7 dpi
(p=0.05) and 10 dpi (p=0.002) (Fig. 2A) and BAL at 7 dpi
(p,0.001) (Fig. 2B) compared to non-depleted control animals.
They also showed recurrent viremia as evidenced by the detection
of SVV viral DNA in WB on days 56 and 70 (Fig. 2A). CD8
depleted animals also experienced higher viral loads 7 dpi in WB
(Fig. 2A) and 3 dpi in the BAL (Fig. 2B) than non-depleted animals
but these differences did not reach statistical significance. We also
measured SVV shedding in saliva since it is well documented that
VZV reactivation results in the shedding of infectious VZV in the
saliva [50,51]. SVV viral DNA was only detected in the buccal
epithelial cells and not the saliva (Fig. 2C and data not shown).
CD8 depleted animals experienced higher SVV viral loads in
buccal epithelial cells at 7 dpi (p=0.0418), while CD4 depleted
animals showed higher SVV viral loads in buccal epithelial cells at
10 (p,0.001) and 14 dpi (p=0.0182) in comparison to non-
depleted control animals (Fig. 2C).
All 16 animals developed varicella (Fig. 3), but the severity and
duration of the rash varied between groups (Table 1). As
previously reported [46], control animals developed lesions
beginning at 7 dpi that began to heal 14 dpi and were completely
resolved 21 dpi (Table 1; Fig. 3A). CD20 depleted animals had
comparable disease severity to control animals (Fig. 3B). However,
CD8 depleted animals continued to display moderate to severe
lesions at 14 dpi that did not resolve until 28 dpi (Table 1; Fig. 3C).
CD4 depleted animals experienced severe and disseminated
varicella rash (Fig. 3D), which also did not begin to heal until 42
dpi (Table 1). Taken together, these data show that in contrast to
CD20 B cells, the absence of CD8 or CD4 T cells results in higher
viral loads and increased disease severity during primary SVV
infection.
Modulation of B cell response by T and B cell depletion
We next investigated the impact of lymphocyte depletion on the
proliferative response of B cells and the generation of SVV-specific
IgG, IgM, and neutralizing antibody responses. Following antigen
encounter, naı ¨ve B cells undergo a proliferative burst and acquire
the memory marker CD27. Therefore, we assessed the prolifer-
ative response of B cells by measuring changes in the expression of
Ki67, a nuclear protein associated with G2-S cell cycle transition,
within two major antigen-experienced B cell subsets: marginal
zone-like (MZ-like) and memory B cell subsets, using FCM. In
BAL from control animals, proliferation of MZ-like B cells began
10 dpi, peaked 14 dpi, and returned to baseline levels 17 dpi
(Fig. 4A). Frequency of Ki67+ memory B cells in BAL of control
animals increased at 7dpi, peaked 10dpi, and returned to baseline
levels 17 dpi (Fig. 4B). In CD20-depleted animals, Ki67+ MZ-like
and memory B cell in BAL were detected 14 dpi as the B cell
compartment began to regenerate (Fig. 4A and 4B). Interestingly,
we detected an earlier onset of proliferation of MZ-like and
memory B cells in BAL in CD8 depleted animals compared to
control animals (Fig. 4A and 4B). Proliferative burst of the MZ-like
B cells peaked 7 days before control animals (7 dpi versus 14 dpi)
and reached a higher level (p,0.0001) before returning to baseline
levels 17 dpi (Fig. 4A). Similarly, the proliferative burst of the
memory B cells was detected 4 days earlier (3dpi versus 7dpi) and
reached a higher peak 7 dpi compared to control animals
(p=0.0003) (Fig. 4B). In contrast, we detected minimal B cell
proliferation with no distinct kinetics (less than 10%) in both the
MZ-like and memory subsets in CD4 depleted animals (Fig. 4A
and 4B, and Table 2).
In PBMCs of control animals, MZ-like and memory B cell
proliferation was detected 7 dpi, peaked 10–14 dpi, before
returning to baseline levels 17 dpi (Fig. 4C and 4D). As described
for BAL, Ki67+ MZ-like and memory B cells were detected 14 dpi
in CD20 depleted animals (Fig. 4C and 4D), coinciding with the
re-appearance of B cells in peripheral blood (Fig. 1). In CD8
depleted animals the proliferative burst of MZ-like and memory B
cells was delayed by 3 days (10 dpi compared to 7 dpi, p=0.008)
(Fig. 4C and 4D) but reached higher peak value 14 dpi in the
memory subset compared to control animals (p,0.001) (Fig. 4D).
As observed in BAL, B cells from CD4 depleted animals showed
minimal proliferation in response to SVV infection (p,0.05 at all
time points examined between 7 and 14 dpi) (Fig. 4C and 4D, and
Table 2).
To assess differences in the magnitude of the proliferative burst,
we measured the area under the curve (AUC) for MZ-like and
memory B cell proliferation between 3 and 17 dpi. This analysis
revealed that the magnitude of the proliferative burst of MZ-like
and memory B cells was significantly reduced in PBMC in CD4
depleted animals compared to control animals (p,0.001). In CD8
depleted animals, memory and MZ-like B cell proliferative burst
was higher in BAL (p=0.025) but MZ-like proliferation was lower
in PBMC compared to controls (p=0.013) (Table 2).
We also measured the impact of T and B cell depletion on
antibody production. To that end, we measured SVV-specific IgM
and IgG titers using standard ELISA and neutralizing antibody
titer using plaque reduction assay. In control and CD8 depleted
animals, SVV-specific IgM titers peaked 10 dpi (average titer
1:2000 and 1:2465, respectively) (Fig. 4E). In contrast, CD20 and
CD4 depleted animals had significantly lower average titers of
1:360 and 1:190, respectively (Fig. 4E, p,0.05). Similarly, control
and CD8 depleted animals generated a robust SVV-specific IgG
response that peaked 21 dpi (average titer 1:15800 and 1:17300
respectively) (Fig. 4F), whereas CD20 and CD4 depleted animals
had significantly reduced IgG antibody production 14, 17, 21, and
CD4 T Cells Are Critical during SVV Infection
PLoS Pathogens | www.plospathogens.org 3 November 2011 | Volume 7 | Issue 11 | e1002367Figure 1. Efficacy of antibody-mediated depletion of immune cells during acute SVV infection. (A–C) Average frequency of CD4 T (A),
CD8 T (B), and CD20 B (C) cells in bronchial alveolar lavage (BAL) of control, CD20 depleted, CD8 depleted, and CD4 depleted animals (n=4/group)
were measured using flow cytometry (FCM). Absolute numbers per ml/blood were then calculated by converting the percentage of these subsets
using complete blood counts obtained at every time point (D–F).
doi:10.1371/journal.ppat.1002367.g001
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Specifically, SVV-specific IgG titers 21 dpi were on average
1:6200 and1:2500 in CD20 and CD4 depleted animals respec-
tively (Fig. 4F). Analysis of the AUC for SVV-specific IgG titers
between 0 and 63 dpi showed that both CD20 depleted and CD4
depleted animals have significantly reduced IgG production
compared to non-depleted control animals (p=0.0245 and
p=0.0193, respectively) (Fig. 4F).
We also assessed neutralizing antibody titers following acute
SVV infection 14 and 70 dpi in all animal groups by measuring
the dilution at which 50% reduction in the number of SVV
plaques was achieved (NT50, Table 3). NT50 titers were
comparable between control and CD8 depleted animals 14 dpi,
and by 70 dpi the titers increased 34- to 90-fold and 8- to 17-fold,
respectively (Table 3). In contrast, CD4 depleted animals had
considerably lower NT50 titers 14 dpi compared to control
animals, which increased 6- to 16-fold by 70 dpi (Table 3). Plasma
obtained from CD20 depleted animals showed no neutralization
ability 14 dpi and very negligible NT50 titers 70 dpi (Table 3).
These data suggest that the resolution of varicella during primary
SVV infection in unvaccinated animals does not require the
presence of neutralizing antibodies.
Modulation of T cell response by B and T cell depletion
We assessed how loss of T and B cells modulated the kinetics
and magnitude of T cell proliferation in BAL and PBMCs in
response to SVV infection. Like B cell responses, after antigen
encounter, naı ¨ve T cells become activated, differentiate into
central and effector memory (CM and EM) T cells and undergo a
robust proliferative burst. We assessed this proliferative burst by
measuring frequency of Ki67+ cells within CM and EM T cell
subsets in BAL and PBMC [46]. In BAL from control animals, T
cell proliferation was detected in all subsets 7 dpi after which the
frequency of Ki67+ T cells gradually declined reaching baseline
levels 17 dpi (Fig. 5A–D, and Table 2). In CD20 depleted animals,
the kinetics and magnitude of proliferation in all four T cell subsets
was similar to that observed in control animals (Fig. 5A–D). The
kinetics of the CD4 T cell proliferation in CD8 depleted animals
was comparable to that observed in control animals. However, the
peak frequency of Ki67+ CD4 CM at 7 dpi for CD8 depleted
animals was significantly larger than that observed for control
animals (p=0.0028) (Fig. 5A). Similarly, the peak frequency of
Ki67+ CD4 EM T cells 10 dpi and 14 dpi was also higher in CD8
depleted animals (p=0.0054, p=0.0058, respectively) (Fig. 5B).
Interestingly the re-appearance of CD4 T cells in the BAL 21 dpi
was not accompanied by an increased frequency of CD4 Ki67+ T
cells (Fig. 5A and 5B). We detected proliferating CD8 T cells in
CD8 depleted animals 17 dpi (Fig. 5C and 5D), which coincides
with the re-appearance of CD8 T cells in these animals (Fig. 1).
CD8 CM proliferation was significantly delayed (10 dpi versus 7
dpi in control animals) and reduced in CD4 depleted animals
(p,0.001 at 7 dpi; p=0.0059 at 14 dpi) (Fig. 5C). Similarly,
proliferation of CD8 EM in CD4 depleted animals was also
delayed (10 dpi versus 7 dpi in control animals, Fig. 5D).
We detected very little proliferation by the CD4 T cells in
PBMC from control animals (Fig. 5E and 5F, and Table 2). On
the other hand, CD8 T cell proliferation was easily detected in
PBMC in control animals (Fig. 5G and 5H, and Table 2). The
frequency of Ki67+ CD8 CM T cells in control animals peaked 7
dpi and returned to baseline 14 dpi, and the frequency of Ki67+
Figure 2. Detection of SVV viral loads in control and depleted animals. SVV viral DNA loads were assessed by quantitative real-time PCR in
(A) whole blood (WB), (B) bronchial alveolar lavage (BAL), and (C) buccal epithelial cell samples from control, CD20 depleted, CD8 depleted, and CD4
depleted animals (n=4/group). Averages6 standard error of the mean (SEM) are shown. * indicates p,0.05 as compared to control animals.
doi:10.1371/journal.ppat.1002367.g002
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21 dpi (Fig 5G and 5H). The kinetics and magnitude of T cell
proliferative burst in CD20 depleted animals were comparable to
those described for control animals (Fig. 5E–H). As described for
the BAL, CD4 T cell proliferation was more robust in CD8
depleted animals compared to controls. Specifically, the frequency
of Ki67+ CD4 CM T cells was significantly higher 10 dpi
(p=0.0138) (Fig. 5E), and that of CD4 EM T cells was
significantly higher 3, 7, 10, 14, and 17 dpi (p,0.01 for all days)
(Fig. 5F) when compared to control animals. Ki67+ CD8 CM and
EM T cells were detected 14 dpi (Fig. 5G and H), which coincided
with the re-appearance of CD8 T cells (Fig. 1). As described for the
BAL, CD4 depleted animals exhibited a significant reduction of
proliferating CD8 CM (p=0.001) and EM (p, 0.01 for 10,14 and
17 dpi) (Fig. 5G and 5H). As previously noted for the BAL,
regeneration of the CD4 T cell compartment was not accompa-
nied by an increase in CD4 T cell proliferation in these animals
(Fig. 5G and 5H).
As described above for B cells, we measured the AUC from 3 to
17 dpi for T cell proliferation to assess the magnitude of the
proliferative burst. This analysis showed that in BAL the
proliferative burst of: 1) CD4 EM T cells was significantly higher
in CD8 depleted animals (p=0.026) and 2) that of CD8 CM was
significantly lower in CD4 depleted animals (p,0.001) compared
to control animals. In peripheral blood: 1) CD8 depleted animals
Figure 3. Representative examples of varicella in control and depleted animals. Varicella rash on the trunk of a representative (A) control,
(B) CD20 depleted, (C) CD8 depleted, and (D) CD4 depleted animal at 10 dpi.
doi:10.1371/journal.ppat.1002367.g003
Table 1. Summary of rash duration, lesion number, and
disease severity of control and experimental animal groups
following acute SVV infection.
Group Rash duration Number of lesions Disease severity
Control 10–14 days ,40 Mild
CD20 depleted 10–14 days ,40 Mild
CD8 depleted 18–21 days .125 Moderate-severe
CD4 depleted 25–28 days .200 severe
The number of lesions for each group was determined by averaging the lesions
observed on the abdomen of each animal within each group at 10dpi. The
disease severity of each group was determined by averaging the assigned
severity score (based on the size and duration of observed vesicles) of each
animal within each group (1–2=mild; 3–4=moderate; 5=severe).
doi:10.1371/journal.ppat.1002367.t001
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and EM (p ,0.001) compared to controls and 2) the CD4 depleted
animals showed a smaller CD8 CM (p=0.02) and EM (p ,0.001)
T cell proliferative burst compared to control animals (Table 3).
Effect of T and B cell depletions on responding T cell
frequency
In addition to comparing the kinetics and magnitude of the T
cell proliferative burst in response to SVV in the different groups,
we determined the frequency of SVV-specific T cells within CM
and EM subsets by measuring frequency of IFNc+ or IFNc+/
TNFa+ following stimulation of PBMC and BAL cells with
overlapping peptide pools that covered SVV ORFs 4, 31, 61, and
63 using intracellular cytokine staining (ICS) (Fig. 6, and Table 2).
Following stimulation with overlapping peptide pools, SVV-
specific CD4 CM and EM T cells in BAL were detected at 7 dpi in
control animals, and their frequencies remained stable until 56 dpi
(Fig. 6A and 6B). SVV-specific CD8 CM and EM T cells were also
detected 7 dpi. Whereas the frequency of SVV-specific CD8 CM
T cells increased from 7 to 21 dpi after which it declined, that of
CD8 EM T cells remained stable until 56 dpi (Fig. 6C and D).
Frequency of SVV-specific CD4 CM T cells were lower in BAL
from CD20 depleted animals 7–21 dpi compared to control
animals (p=0.01, 0.008 and 0.03 respectively, Fig. 6A). The
frequencies of SVV-specific CD8 CM in BAL were initially
comparable between CD20 depleted animals and controls but
decayed faster in CD20 depleted animals 21 dpi (p,0.001,
Fig. 6C). The frequency of SVV-specific CD8 EM was also
Figure 4. Impact of T and B cell depletion on kinetics and magnitude of B cell proliferation and IgG/IgM production following SVV
infection. Frequency of proliferating (Ki67+) B cells within marginal zone-like and memory subsets in BAL (A, B) and PBMC (C, D) was measured using
FCM. Data points for B cell proliferation in CD20-depleted animals are not shown 0–14 dpi as there were no B cells in circulation during this time
period. Average SVV-specific IgM (E) and IgG (F) end point titers6 SEM in control, CD20 depleted, CD8 depleted, and CD4 depleted animals (n=4/
group) were determined by standard ELISA.* indicates p,0.05 as compared to control animals.
doi:10.1371/journal.ppat.1002367.g004
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and 0.04 respectively, Fig. 7D). After day 21, frequency of SVV-
specific T cells was comparable in CD20 depleted and control
animals. In CD8 depleted animals the frequency of responding T
cells within CD4 CM subset was lower than that detected in control
animals 7–21 dpi (p=0.04, p=0.006 and p=0.04 respectively,
Fig. 6A). Similarly the frequency of responding T cells within CD4
EM was lower 14 dpi compared to controls (p=0.0413) (Fig. 6B).
SVV-specific CD8 T cells were first detected in CD8 depleted
animals 21 dpi, which corresponds to the re-appearance of the CD8
T cells in these animals, albeit with lower frequency within the CD8
CM subset compared to control animals (p,0.001, Fig. 6C). SVV-
specific CD4 T cells appeared in CD4 depleted animals 28 dpi and
their frequencies within the CM and EM subsets were comparable
to those observed in control animals. It should be noted that 21–28
dpi, the number of CD8 and CD4 T cells is still much lower in CD8
and CD4 T cell depleted animals respectively compared to controls.
Therefore, although the relative frequencies of responding T cells
within CM and EM subsets may be comparable, the absolute
number of SVV specific CD8 and CD4 T cells is much lower in
CD8 and CD4 depleted animals respectively compared to controls.
In contrast, frequency of SVV-specific CD8 T cells within CM and
EM subsets in CD4 depleted animals were lower than those
observed in control animals at several time points (14 and 21 dpi in
CD8 CM p=0.007 and ,0.001, respectively; and 7 and 14 dpi in
CD8 EM p=0.02 and 0.01, respectively, Fig. 6C and 6D).
In PBMCs, SVV-specific T cells were detected 7 dpi in control
animals and their frequency remained stable until 56 dpi (Fig. 6E–
H). In CD20 depleted animals, SVV-specific T cells were also
detected 7 dpi, but the frequencies of CD4 EM and CD8 EM were
lower compared to control animals (p=0.03 and p=0.007,
respectively) (Fig. 6E–H). SVV-specific CD4 T cells in CD8
depleted animals were also detected with similar kinetics and
frequencies as seen in control animals (Fig. 6E and 6F). Although
SVV-specific CD8 T cells were also detected 7 dpi in CD4
depleted animals, their frequency was initially lower (7 dpi
p,0.001 for both CD8 CM and EM, Fig. 6G and 6H). SVV-
specific CD8 T cells in CD8 depleted animals were detected 21 dpi
(Fig. 6G and 6H), concomitant with the re-appearance of CD8 T
cells in these animals (Fig. 1). SVV-specific CD4 T cells were
detected 28 dpi in CD4 depleted animals (Fig. 6E and 6F),
corresponding with the re-appearance of CD4 T cells in these
animals (Fig. 1). As stated above, although the relative percentage
of responding T cells within CM and EM subsets in the T cell
depleted animals may be comparable to those of control animals,
the number of and CD8 and CD4 T cells is still much lower in
CD8 and CD4 T cell depleted animals respectively compared to
controls.
To determine the magnitude of the frequency of T cells in
response to SVV peptide stimulation, we measured the AUC for
SVV-specific T cells in all four animals groups between 7 and 35
Table 2. Summary of effect of immune cell depletions on the anti-SVV response.
Control animals CD20 depleted animals CD8 depleted animals CD4 depleted animals
B cell proliferation Peaked at 10–14 dpi N/A Earlier onset, higher magnitude Delayed onset, significantly
reduced magnitude
CD4 T cell proliferation Peaked at 7 dpi Similar to control animals Similar kinetics, higher magnitude N/A
CD8 T cell proliferation Peaked at 7 dpi Similar to control animals N/A Delayed onset, significantly
reduced magnitude
Frequency of SVV-specific
CD4 T cell
Peaked at 7 dpi Lower frequency at 7/14 dpi Lower frequency at 14 dpi in
BAL
N/A
Frequency of SVV-specific
CD8 T cell
Peaked at 7 dpi Lower frequency at 7/14 dpi N/A Lower frequency at 7/14 dpi
CD4 grzmB+ T cell Peaked at 3–7 dpi Significantly lower magnitude
at 7 dpi in CD4 CM PBMC
Significantly lower magnitude
at 7 dpi in CD4 CM PBMC
N/A
CD8 grzmB+ T cell Peaked at 7 dpi Similar to control animals N/A Significantly lower magnitude at
7 dpi in CD4 CM in BAL & PBMC
Hallmarks of the immune response during acute SVV infection were compared between control and depleted animals. N/A indicates that comparison could not be
carried out due to the depletion of the T or B cell subset in question.
doi:10.1371/journal.ppat.1002367.t002
Table 3. Neutralizing antibody response following acute SVV
infection.
Animal I.D. Group 14 dpi 70 dpi
24943 control 42 53
25170 control 24 2178
25339 control 280 9564
27577 control 177 9862
25152 CD4 depl 21 348
25111 CD4 depl ND 481
24952 CD4 depl ND 1869
24993 CD4 depl 9 119
25343 CD8 depl 22 381
25371 CD8 depl 89 855
26842 CD8 depl 49 456
26108 CD8 depl 121 975
25833 CD20 depl ND 60
25905 CD20 depl ND 20
25920 CD20 depl ND 33
25892 CD20 depl ND 65
Neutralization titers are expressed as the reciprocal of the plasma dilution that
neutralized 50% or more of the plaques compared to control cultures (no
plasma added). Neutralization titers less than the starting dilution of 1:2 are
listed as ND (not determined).
doi:10.1371/journal.ppat.1002367.t003
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PLoS Pathogens | www.plospathogens.org 8 November 2011 | Volume 7 | Issue 11 | e1002367Figure 5. Impact of T and B cell depletion on the kinetics and magnitude of T cell proliferation following acute SVV infection.
Frequency of proliferating (Ki67+) CD4 and CD8 T cells within central and effector memory subsets was measured in BAL (A–D) and PBMC (E–H) by
FCM. Data points for CD4 T cell Ki67+ frequency in CD4-depleted animals are not shown 7–21 dpi as there were no CD4 T cells in circulation during
this time period. Similarly data points for Ki67+ CD8 T cell frequency are not shown 0–14 dpi as there were no CD8 T cells detected during this period.
* indicates p,0.05 as compared to control animals.
doi:10.1371/journal.ppat.1002367.g005
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PLoS Pathogens | www.plospathogens.org 9 November 2011 | Volume 7 | Issue 11 | e1002367Figure 6. Impact of T and B cell depletion on frequency of SVV-specific T cells. The frequency of SVV-specific T cells in BAL and PBMCs was
measured by intracellular cytokine staining following stimulation with overlapping peptide pools covering ORFs 4, 31, 61 and 63. The average
percentage of responding (IFNc+ and IFNc+TNFa+) T cells 6 SEM within CD4 CM, CD4 EM, CD8 CM and CD8 EM subsets in BAL (A–D) and PBMCs (E–
H) is shown. Responses detected on day 0 were on average ,0.5% and were subtracted from subsequent time points. * indicates p,0.05 as
compared to control animals.
doi:10.1371/journal.ppat.1002367.g006
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PLoS Pathogens | www.plospathogens.org 10 November 2011 | Volume 7 | Issue 11 | e1002367Figure 7. Frequency of granzyme (grzm) B+ T cells after SVV infection. Frequency of grzmB+ T cells within CD4 and CD8 CM and EM subset
was assessed by FCM in BAL (A–D) and PBMC (E–H). Average percentages of grzmB+ cells 6 SEM are shown. Data points for CD4 T cell grzmB+
frequency in CD4-depleted animals are not shown 7–21 dpi as the frequency of CD4 T cells in circulation was too low during this time period.
Similarly, data points for grzmB+ CD8 T cell frequency are not shown 0–14 dpi as there were no CD8 T cells detected during this period. * indicates
p,0.05 as compared to control animals.
doi:10.1371/journal.ppat.1002367.g007
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specific CD4 CM T cell response is significantly reduced in CD20
and CD8 depleted animals (p=0.0155 and p=0.0036, respec-
tively); (2) SVV-specific CD8 CM response are significantly
reduced in CD20 and CD4 depleted animals (p=0.0146 and
p=0.0023, respectively); and (3) SVV-specific CD8 EM response
is significantly reduced in CD4 depleted animals (p=0.0445)
compared to control animals.
The impact of T and B cell depletion on the development
of cytolytic T cells
SVV and VZV infections are associated with the development
of cytolytic CD4 and CD8 T cells [46,52]. In order to determine
how loss of lymphocyte subsets alters frequency of T cells with
cytolytic potential, we measured the changes in granzyme B
(grzmB) expressing CD4 and CD8 T cells (Fig 7, and Table 2). In
BAL, we detected an increase in the frequency in grzmB+ CD4
CM 7 dpi in all animals (excluding CD4 depleted animals), which
was followed by a quick return to baseline 14 dpi (Fig. 7A).
Frequency of grzmB+ CD4 EM increased 3 dpi in control and
CD8 depleted animals and 7 dpi in CD20 depleted animals
(Fig. 7B). This increase in frequency was sustained until 28 dpi
after which frequencies return to baseline levels (Fig. 7B). In CD4
depleted animals, grzmB+ CD4 CM and EM were detected 21 dpi
(Fig. 7A and 7B) coinciding with the reappearance of CD4 T cells
in these animals (Fig. 1) and peaked in frequency 35 dpi. As
described for CD4 T cells, the frequency of grzmB+ CD8 CM T
cells increased 7 dpi in all animals (excluding CD8 depleted
animals) before returning to baseline 21 dpi (Fig. 7C). However,
this increase was significantly reduced in CD4 depleted animals
compared to control animals (p ,0.001) (Fig. 7C). The frequency
of grzmB+ CD8 EM increased 10 dpi in all groups (with the
exception of CD8 depleted animals), followed by a small decrease
and the establishment of a new set point (Fig. 7D). We detected
grzmB+ CD8 CM and EM T cells in CD8 depleted animals 14
dpi, after which the frequency remained stable for the duration of
the study (Figs. 7C and D).
A similar pattern of changes in grzmB+ T cell frequencies was
observed in PBMCs. We detected a small increase in frequency of
grzmB+ CD4 CM 7 dpi in control animals, followed by a return to
baseline levels 10 dpi (Fig. 7E). This increase was significantly
lower in CD8 and CD20 depleted animals compared to control
animals (p ,0.001 in both cases) (Fig. 7E). The frequency of
grzmB+ CD4 EM T cells increased 10 dpi in CD8 depleted
animals and 14 dpi in CD20 depleted and control animals
(Fig. 7F), before reaching the same peak magnitude 17 dpi
followed by the establishment of a new set point 21 dpi (Fig. 7F). In
the CD8 CM subset, the frequency of grzmB+ peaked sharply 7
dpi in all groups, albeit at a significantly lower level in CD4
depleted animals (p,0.001), before returning to baseline levels 10
dpi (Fig. 7G). The frequency of grzmB+ CD8 EM increased 10 dpi
in all groups, peaked 17 dpi before establishing a new set point
(Fig. 7H). We detected grzmB+ CD8 CM and EM in CD8
depleted animals 14 dpi, which coincides with the re-appearance
of CD8 T cells in these animals (Fig. 7H).
Finally, we measured the AUC between 3 and 21 dpi to assess
the differences in grzmB expression between the different groups
following SVV infection. In BAL, CD20 depleted animals have a
significantly reduced frequency of grzmB+ CD4 EM T cells
compared to control animals (p=0.025). In addition, CD4
depleted animals have a significantly reduced frequency of
grzmB+ CD8 CM T cells compared to control animals
(p=0.0147). In peripheral blood, the grzmB+ CD4 CM response
was lower in both CD8 (p=0.0265) and CD20 (p=0.0356)
depleted animals. Moreover, the magnitude of grzmB expression
in the CD8 CM subset is lower in CD4 depleted animals
(p=0.0002).
Discussion
Several observations suggest that VZV infection is controlled via
cellular immunity rather than humoral immunity. Specifically,
children afflicted with T cell deficiencies are at increased risk from
progressive varicella. In contrast, children diagnosed with B cell
deficiencies such as agammaglobulinemia exhibit uncomplicated
varicella [17,18,19,20,21]. Moreover, whereas VZV antibody
administration after contagion but before the appearance of
exanthem has been shown to block progression of systemic
varicella [53], administration after the onset of varicella has no
effect on disease progression [12]. Finally, despite the presence of
high VZV-specific IgG titers, aged persons are at increased risk
from VZV reactivation than young adults. However, the exact
contributions of T cell and B cell immunity to the resolution of
acute VZV infection in unvaccinated individuals have not yet been
experimentally elucidated. This knowledge would play a critical
role in the design of second-generation vaccines against VZV.
SVV is also a neurotropic a herpesvirus and a homologue of
VZV that causes varicella in nonhuman primates. We have
recently shown that SVV infection of juvenile rhesus macaques
recapitulates the hallmarks of primary VZV infection in children
including the development of a vesicular rash, the generation of T
and B cell responses and the establishment of latency in sensory
ganglia [46]. In this model, the animals are infected intrabronchi-
ally, which bypasses the early phase of VZV incubation/
replication in the head and neck region, resulting in an incubation
period of approximately 10 days. Direct inoculation of SVV into
the lungs might also result in altered viral amplification since VZV
replicates efficiently in tonsilar memory CD4 T cells [48,49].
Although, this incubation period is slightly shorter than that of
VZV (10–21 days), the detection of T and antibody responses in
SVV-infected macaques in relation to the onset of the rash occurs
with comparable kinetics as those described for VZV [12].
Moreover, whereas natural and experimental SVV infection
results in significant morbidity and mortality in other nonhuman
primate species, infection of rhesus macaques with SVV results in
a milder disease that more closely resembles varicella in humans
[54,55]. These observations suggest that SVV infection of rhesus
macaques is a robust model with which to investigate the
contribution of CD4 T cell, CD8 T cells and B cell immunity to
the control of acute VZV infection.
Our results show that depletion of CD20 B cells and loss of early
antibody production does not alter viral loads or disease severity.
As expected, CD20-depleted animals were significantly compro-
mised in their ability to generate SVV-specific IgM and IgG
antibodies. Our data also suggest that the production of
neutralizing antibodies is not required for resolution of varicella
as the CD20 animals failed to generate a robust neutralizing
antibody response yet had uncomplicated varicella. These data are
in agreement with clinical observations that the VZV specific
antibody response generated during acute VZV infection
contributes little to the immune response to VZV [47]. Indeed,
children with congenital agammaglobulinemia experience uncom-
plicated varicella [56]. Moreover, passive antibody therapy is only
successful when administered within the first 72 hours following
VZV exposure [24,25] and has no effect on disease progression if
administered after the appearance of the rash [12]. We also
observed similar kinetics and magnitude in the frequency of
proliferating T cells in BAL and PBMCs of CD20 depleted
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and kinetics of T cell proliferation were unchanged in CD20
depleted animals, we detected a lower frequency of SVV-specific
T cells 7 and 14 dpi as detected by ICS following peptide
stimulation (ORFs 4, 31, 61 and 63) in these animals. One possible
explanation for these results is that B cells are an important source
of antigen presenting cells in this in vitro assay, and their absence
results in the detection of a lower frequency of responding T cells.
Alternatively the absence of B cells in vivo could lead to a change in
immunodominance profile, resulting in T cells in CD20 depleted
animals preferentially responding to additional ORFs not included
in our peptide pools. The SVV-induced increase in frequency of
grzmB+ T cells in CD20 depleted animals was similar in kinetics
and magnitude to that observed in control animals with the
exception that frequency of grzmB+ CD4 CM T cells in PBMC 7
dpi was significantly lower than control animals. This decrease
could be due to the fact that B cells contribute to the activation of
CD4 T cells in the peripheral blood. Overall, these data are
reminiscent of the documented clinical observations and strongly
suggest that the development of antibody response during primary
SVV/VZV infection is not critical to the resolution of the acute
infection. Our data also suggest a potential role for B cells in
modulating the specificity of the T cell response, but more
conclusive analyses are required to specifically address that
question.
Depletion of CD8 T cells resulted in slightly increased viral
loads in whole blood and BAL samples but these differences did
not reach statistical significance. Interestingly, the time points at
which higher viral loads are observed in CD8 depleted animal
differ between the BAL and WB, indicative of potentially different
mechanisms of control. In the BAL slightly higher viral loads are
detected 3 dpi. This is too early to suggest involvement of the CD8
T cell response. Indeed, the antibody that we used for CD8 T cell
depletion targets all CD8 + lymphocytes, which in the macaque
include NK cells. Thus, it is more likely that the higher viral load
detected 3 dpi in CD8 depleted animals is a reflection of NK cell
depletion rather than CD8 T cell depletion. In contrast, we
observed a higher viral load 10 dpi in WB in CD8 depleted
animals, which is more indicative of a defect in the CD8 T cell
response. These observations are similar to clinical observations
that severe varicella is associated with an absence of NK cells and
primed CD8+ T cells responses in children [57]. CD8 depleted
animals also experienced a somewhat more prolonged varicella
episode and higher number of vesicles. Interestingly, we detected
that depletion of CD8 T cells results in an increase in CD4 and B
cell proliferation compared to control animals. This compensatory
mechanism could have alleviated the consequences associated with
loss of CD8 T cell function.
Finally, depletion of CD4 T cells resulted in disseminated
varicella, higher viral loads and sustained viremia although
complete CD4 T cell depletion was not achieved until 10 dpi.
The difference in disease severity between CD4 and CD8 T cell
depleted animals cannot be explained by differences in the
duration of T cell depletion. In fact, complete CD4 T cell
depletion was not achieved until 10 dpi and was very transient in
the BAL compared to CD8 T cell depletion and lasted 7 days in
PBMC (10–17 dpi), whereas CD8 T cells were depleted for 10
days in BAL and 17 days in PBMC (0–21 dpi). The severe
varicella observed in CD4 depleted animals is in line with clinical
observations that HIV+ children fail to generate a T cell response
and suffer progressive-disseminated varicella as well as additional
complications such as varicella pneumonia, hepatitis, coagulopa-
thy and meningoencephalitis [16]. Additionally, HIV patients are
more susceptible to herpes zoster during the phase in which
absolute numbers of CD4 T cells decline [12], highlighting the
importance of CD4 T cell responses in controlling VZV infection.
It is possible that the use of anti-CD4 depleting antibody resulted
in the depletion of CD4+ macrophages. However, we were not
able to detect reduced frequency of monocytes/macrophages in
CD4 depleted animals using CD14 and HLA-DR as markers (data
not shown). It is also possible that the depleting antibody resulted
in the loss of CD4+NK T cells. However, a difference in viral
loads between CD4 depleted and control animals is not detected
until 7 dpi, indicative of a defect in adaptive rather than innate
immunity. Indeed, CD4-depleted animals experienced delayed
and reduced CD8 T cell proliferative bursts in both peripheral
blood and BAL. This delay correlated with a significant decrease
in the frequency of SVV-specific CD8 T cells that were detected
by ICS. Moreover, the appearance of SVV-induced grzmB+ CD8
CM T cells was also reduced in these animals. Similarly, B cell
proliferation and IgG, IgM and neutralizing antibody production
was compromised in CD4 depleted animals. Since data from our
CD20 and CD8 depleted animals suggests a minimal role for these
lymphocyte subsets in the resolution of acute SVV infection, it is
very likely that the severe disease experiences by CD4-depleted
animals is a consequence of a compromised CD4 T cell response.
Taken together, data presented in this manuscript suggest that
the CD4 T cell response executes unique effector functions that
are critical to the resolution of SVV/VZV infection. Although we
cannot discount the possibility of synergism between the loss of B
and CD8 T cell responses, our own depletion studies and data
from additional studies support the hypothesis that CD4 T cells
play a unique role during SVV/VZV infection. For instance, in
addition to their role in recruiting CD8 CTL to sites of infection
via release of Th1 cytokines [12,58], CD4 T cells can kill VZV-
infected cells [31,59,60,61]. Moreover, studies that characterized
the VZV-specific T cell response in patients with VZV-induced
uveitis revealed that CD4 T cells were responsible for the bulk of
the T cell response [62,63]. VZV-specific CD4 T cells are also
preferentially detected following re-exposure to VZV [64]. Taken
together, the data presented in this manuscript and from
previously published studies strongly suggest that CD4 T cells
play a critical role in coordinating the anti-VZV/SVV response
during primary infection that goes beyond providing help for CD8
and B cells. Additionally, a recent study investigating CMV-
specific immune responses in CMV-seropositive renal transplant
patients reported a positive correlation between low CD4 T cell
counts and increased CMV DNA in the plasma of patients,
suggesting a role for CD4 T cell immunity in controlling CMV
reactivation [65]. This report, along with the data presented in this
manuscript, suggest that the role of CD4 T cell responses in
controlling herpesvirus infections may have previously been
under-estimated. More investigations into this topic are needed
to uncover the mechanisms by which CD4 T cells participate in
the control of herpes viral infections.
In summary, using SVV infection of rhesus macaques as a
model of VZV infection [46], we show for the first time in vivo the
contribution of cellular immunity versus humoral immunity during
acute SVV infection. Our results indicate that similar to clinical
findings regarding VZV control in children, the ability of young
rhesus macaques to control acute SVV infection is mediated by T
cell immunity rather than humoral immunity. More importantly,
our data strongly suggest that CD4 T cells mediate effector
functions that are more important that providing help for antibody
or CD8 T cell response in the resolution of acute SVV infection.
Future studies will dissect the effector functions of CD4 T cells that
are important for protection and elucidate the role of CD4 and
CD8 T cell immunity in the protection against SVV reactivation.
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Ethics statement
The study was carried out in strict accordance with the
recommendations described in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health, the Office
of Animal Welfare and the United States Department of
Agriculture. All animal work was approved by the Oregon
National Primate Research Center Institutional Animal Care and
Use Committee (IACUC protocol # 0779). The ONPRC has
been continuously accredited by the American Association for
Accreditation of Laboratory Animal Care since 1974 (PHS/
OLAW Animal Welfare Assurance # A3304-01). All procedures
were carried out under Ketamine anesthesia in the presence of
veterinary staff and all efforts were made to minimize animal
suffering.
Cells and virus
SVV was propagated in primary rhesus fibroblasts (1u RF) at
37uC in 175 cm
2 flasks with DMEM supplemented with 10%
FBS. SVV-infected 1u RF were frozen in FetalPlex with 10%
DMSO, stored in LN2, and assayed by plaque assay. SVV cell
lysate was obtained by scraping SVV-infected 1u RF at the height
of cytopathic effect (CPE) followed by concentration, and then
sonication using 7 pulses of 70–80W (Sonicator 3000, Misonix).
The sonicated cell-resuspension was pelleted by centrifugation at
2000rpm for 5 min and frozen at 280uC.
Animals and sample collection
16 colony-bred Rhesus macaques (Macaca mulatta, RM) 3–4 years
of age and of Indian origin were used in these studies. They were
housed and handled in accordance with the Oregon National
Primate Research Center Institutional Animal Care and Use
Committee. To deplete CD4 T cells, 4 RM received the humanized
monoclonal antibody OKT4-HulgG on 23, 0, and 7 days post-
infection(dpi) at a dose of 50mg/Kg.To deplete CD8T cells,4 RM
received the mouse-human chimeric monoclonal antibody cM-
T807 on 23 dpi at a dose of 10mg/Kg, and on 0, 3, and 7 dpi at a
dose of 5mg/Kg. To deplete B cells, 4 RM were administered the
mouse-human chimeric antibody Rituxan on 27, 0, and 7 dpi at
20mg/Kg.All animals were inoculated intrabronchially with 4610
5
PFU SVV as previously described [46]. Blood, bronchial alveolar
lavage (BAL), and ,1 ml saliva samples were collected on days
214, 0, 3, 7, 10, 14, 17, 21, 28, 35, 42, 49, 56, 63, and 70. The
absolute numbers of lymphocytes/mL of blood were obtained using
a Hemavet (Drew Scientific, Inc., Dallas, TX). BAL samples were
pelleted and resuspended in RPMI supplemented with 10%FBS,
streptomycin/penicillin, and L-glutamine. Peripheral blood mono-
nuclear cells (PBMCs) and plasma were isolated by centrifugation
over a histopaque gradient (Sigma) as per the manufacturer’s
recommendation. Saliva samples were centrifuged in order to
separate the buccal epithelial cells from the saliva.
DNA extraction and quantitative PCR
DNA was extracted from heparinized whole blood, BAL cells,
saliva and buccal epithelial cells using the Qiagen genomic DNA
extraction kit (Qiagen) and SVV DNA loads were determined by
real-time PCR using primers and probes specific for ORF21 using
the ABI 7700 and ABI StepOne instruments (Applied Biosystems,
Foster City, CA) exactly as previously described [46].
Measurement of T and B cell proliferation
PBMC and BAL cells were surface stained with antibodies against
CD8b (Beckman Coulter), CD4 (eBioscience, San Diego, CA),
CD28, and CD95 (BioLegend, San Diego, CA) to delineate the naive
(CD28+CD952), central memory (CD28+CD95+), and effector
memory (CD282CD95+) T cell subsets. PBMC and BAL cells were
also surface stained with antibodies against CD20 (Beckman Coulter,
Brea, CA), CD3 (BD Pharmingen, San Diego, CA), IgD (Southern
Biotech), and CD27 (BioLegend) to delineate the naı ¨ve
(IgD+CD272), MZ-like (IgD+CD27+), memory (IgD2CD27+)B
cell subsets. Cells were fixed and permeabilized according to
manufacturer recommendations (Biolegend) before the addition of
Ki67-specificantibody(BDPharmingen).Thesampleswereanalyzed
using the LSRII instrument (Beckton, Dickinson and Company, San
Jose, CA) and FlowJo software (TreeStar, Ashland, OR).
Granzyme B staining
PBMC and BAL cells were surface stained using antibodies
against CD4, CD8b, CD28, and CD95 as described for Ki67
staining. Cells were fixed and permeabilized using fixation buffer
(BioLegend), and then stained intracellularly using an antibody
against granzyme B (BD Pharmingen). Samples were analyzed
using the LSRII instrument and FlowJo software.
Intracellular cytokine staining
PBMC and BAL cells were either stimulated with SVV lysate
(1 ug) for 12 h followed by incubation with Brefeldin A for 6 h, or
were incubated with one of the following SVV peptides and
Brefeldin A (Sigma, St Louis, MO) for 6 h: open reading frame
(ORF) 4; ORF31; ORF61; or ORF63. After stimulation cells were
surface stained with antibodies against CD4, CD8b, CD28, and
CD95 as described for Ki67 staining. Samples were fixed and
permeabilized using fixation buffer (BioLegend), and then stained
using antibodies against IFNc and TNFa (eBioscience). Samples
were analyzed using the LSRII instrument and FlowJo software.
Enzyme-linked Immunosorbent Assay (ELISA)
ELISA plates were coated with SVV lysate overnight at 4uC,
washed three times with 0.05% Tween-PBS, and incubated with heat-
inactivated (56uC, 30 min) plasma samples in 3-fold dilutions in
triplicate for 1 h. After washing three times with 0.05% Tween-PBS,
horseradish peroxidase (HRP)-conjugated anti-rhesus IgG (Nordic
Immunology, The Netherlands) or anti-rhesus IgM (Brookwood
Biomedical, Birmingham, AL) was added for 1 h, followed by addition
of o-phenylenediamineN2HCl (OPD) substrate (Sigma, St Louis, MO).
The reaction was stopped with the addition of 1 M HCl. IgG and IgM
endpoint titers were calculated using log-log transformation of the
linear portion of the curve, and 0.1 optical density (OD) units as cut-off.
IgG and IgM titers were standardized using a positive control sample
that was included in every ELISA plate.
Plaque reduction assay
Neutralizing antibody titers were evaluated as previously
described [66] by measuring the plasma dilution at which 50%
reduction in SVV plaques was achieved (NT50). Serial two-fold
dilutions of heat-inactivated monkey plasma from 0, 14, and 70
dpi were incubated with approximately 150pfu of SVV for 30
minutes at 37uC. Virus/plasma samples were then added to
duplicate primary rhesus fibroblast cell monolayers seeded on 12-
well plates and incubated for 4 days at 37uC. Monolayers were
fixed with methanol and then stained with crystal violet to
visualize the SVV plaques.
Statistical analysis
Repeated measures of ANOVA was used to explore differences
between groups. Pair-wise comparisons at each time point were
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determined at the level of 0.05. First order autoregressive
covariance structure was used to account for within subject
correlation. Due to the small sample size, other complicated
covariance analyses was not considered.
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